THE GILL LAB

Our focus on pushing the frontier of CAR therapies has led to several paradigm-shifting innovations including CART123 for acute myeloid leukemia, CAR macrophages for solid tumors, and pairing CART33 treatment with CRISPR-edited CD33-deficient bone marrow transplants. Each of these technologies is currently being pursued in early phase clinical trials, and promises to alter the landscape of cancer immunotherapy and pave the way for further innovation.

Latest News

Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers Wednesday, September 27, 2023
In the Lord of the Rings, there was “one ring to rule them all.” Now, a team of researchers is developing their own single ruler, an approach to CAR T-cell therapy that could treat all forms and types of blood cancer.
Two-pronged immunotherapy approach could treat most blood cancers Thursday, August 31, 2023
Strategy using genetically engineered T cells would attack cancer while sparing healthy blood stem cells.
Strides made in grant awarded to develop genetically engineered stem cell products to fight gastroesophageal cancer Wednesday, July 19, 2023